for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Citius Pharmaceuticals Inc

CTXR.O

Latest Trade

1.04USD

Change

0.01(+0.98%)

Volume

361,311

Today's Range

1.02

 - 

1.09

52 Week Range

0.40

 - 

1.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Citius Pharmaceuticals says Received Written Notice From Nasdaq That Co Had Regained Compliance With Rule 5550(A)(2)

* CITIUS PHARMACEUTICALS - RECEIVED WRITTEN NOTICE FROM NASDAQ THAT CO HAD REGAINED COMPLIANCE WITH RULE 5550(A)(2) Source text - https://bit.ly/3ef4JrB Further company coverage:

BRIEF-Citius Receives FDA Response On Pre-IND Application For Acute Respiratory Distress Syndrome Treatment In Patients With Covid-19

* CITIUS RECEIVES FDA RESPONSE ON PRE-INVESTIGATIONAL NEW DRUG (PIND) APPLICATION FOR ITS INDUCED MESENCHYMAL STEM CELLS (IMSCS) TO TREAT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN PATIENTS WITH COVID-19

BRIEF-Citius Pharmaceuticals Says Files Prospectus Related To Sale Or Other Disposition Of Upto 4 Million Shares By Selling Stockholders

* CITIUS PHARMACEUTICALS - FILES PROSPECTUS RELATED TO SALE OR OTHER DISPOSITION OF UPTO 4 MILLION SHARES BY SELLING STOCKHOLDERS Source text: (https://bit.ly/2BEcYjx) Further company coverage:

BRIEF-Citius Announces Expanded Access Program For Investigational Phase 3 Mino-Lok

* CITIUS ANNOUNCES EXPANDED ACCESS PROGRAM FOR INVESTIGATIONAL PHASE 3 MINO-LOK®

BRIEF-Citius Announces $7.5 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $7.5 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES Source text for Eikon: Further company coverage:

BRIEF-Citius Says Data On Nc-Mscs To Be Presented At ASGCT Annual Meeting

* CITIUS ANNOUNCES DATA ON NOVECITE MESENCHYMAL STEM CELLS (NC-MSCS) TO BE PRESENTED AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) ANNUAL MEETING

BRIEF-Citius Announces Pre-IND Submission To FDA For A Novel Stem Cell Therapy For ARDS In Covid-19

* CITIUS ANNOUNCES PRE-IND SUBMISSION TO FDA UNDER THE CORONAVIRUS TREATMENT ACCELERATION PROGRAM FOR A NOVEL STEM CELL THERAPY FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN COVID-19

BRIEF-Citius Pharmaceuticals Files Prospectus Relates To Sale Of Some Shares

* CITIUS PHARMACEUTICALS FILES PROSPECTUS RELATES TO SALE OR OTHER DISPOSITION OF UP TO 6.7 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS Source text: https://bit.ly/2JVijDZ Further company coverage:

BRIEF-Citius Signs Exclusive Option With Novellus To License Novel Stem-Cell Therapy For Acute Respiratory Distress Syndrome (Ards) Associated With Covid-19

* CITIUS SIGNS EXCLUSIVE OPTION WITH NOVELLUS TO LICENSE NOVEL STEM-CELL THERAPY FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ASSOCIATED WITH COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Citius Pharmaceuticals To Sell Up To 1.4 Mln Shares Of Co's Common Stock

* CITIUS PHARMACEUTICALS - TO SELL OR OTHER DISPOSITION FROM TIME TO TIME OF UP TO 1.4 MILLION SHARES OF CO'S COMMON STOCK Source : https://bit.ly/2JdehV7 Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Citius Announces $2 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET Source text for Eikon: Further company coverage:

BRIEF-Citius Reports Progress In Hemorroid Treatment Program

* CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS

BRIEF-Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co

* CITIUS PHARMACEUTICALS INC - ON NOV 27, , BOARD APPOINTED JAIME BARTUSHAK AS CFO AND PRINCIPAL FINANCIAL OFFICER OF COMPANY, EFFECTIVE NOV. 27, 2017 Source text: (http://bit.ly/2iwTNyZ) Further company coverage:

BRIEF-Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing

* Citius Pharmaceuticals Inc - files for mixed shelf offering of up to $50 million - SEC filing Source text: (http://bit.ly/2zKcjdY) Further company coverage:

BRIEF-Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial

* Citius Pharmaceuticals, Inc. Receives "fast track" designation by FDA for mino-lok™ investigational trial Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Citius Pharmaceuticals provides phase 3 update on Mino-Lok clinical trial following FDA meeting

* Citius Pharmaceuticals, Inc provides phase 3 update on Mino-Lok™ clinical trial following FDA meeting

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up